{"id":4018,"date":"2019-08-24T15:24:08","date_gmt":"2019-08-24T15:24:08","guid":{"rendered":"https:\/\/www.futuresandoptions.gr\/en\/?p=4018"},"modified":"2019-08-24T16:19:40","modified_gmt":"2019-08-24T16:19:40","slug":"understanding-myovant-sciences-ltd-myovs-and-tg-therapeutics-inc-nasdaqtgtxs-results","status":"publish","type":"post","link":"https:\/\/www.futuresandoptions.gr\/en\/understanding-myovant-sciences-ltd-myovs-and-tg-therapeutics-inc-nasdaqtgtxs-results\/","title":{"rendered":"Understanding Myovant Sciences Ltd. (MYOV)\u2019s and TG Therapeutics Inc. (NASDAQ:TGTX)\u2019s results"},"content":{"rendered":"\n
In this article, we\nreview the NASDAQ results for two biotechnology companies, Myovant Sciences Ltd\n(ticker: MYUOV) and TG Therapeutics Inc (ticker: NASDAQ:TGTX). We will compare\ntheir risk, analyst recommendations, profitability, dividends, institutional\nownership, earnings and valuation.<\/p>\n\n\n\n
Valuation and Earnings<\/h2>\n\n\n\n
<\/td>
Gross Revenue <\/td>
Price\/Sales Ratio <\/td>
Net Income <\/td>
Earnings Per Share <\/td>
Price\/Earnigs Ratio <\/td><\/tr>
Myovant Sciences Ltd. <\/td>
\n 15\n <\/td>
\n 0.00\n <\/td>
\n N\/A\n <\/td>
\n -4.08\n <\/td>
\n 0.00\n <\/td><\/tr>
TG Therapeutics Inc. <\/td>
\n 7\n <\/td>
\n 4207.88\n <\/td>
\n N\/A\n <\/td>
\n -2.15\n <\/td>
\n 0.00\n <\/td><\/tr><\/tbody><\/table>\n\n\n\n
Table\n1 showcases the gross revenue, earnings per share and valuation of Myovant\nSciences Ltd. and TG Therapeutics Inc.<\/p>\n\n\n\n
Profitability<\/h2>\n\n\n\n
Table\n2 demonstrates the net margins, return on equity and return on assets of\nMyovant Sciences Ltd. and TG Therapeutics Inc.<\/p>\n\n\n\n
Myovant\nSciences Ltd.\u2019s Current Ratio and Quick Ratio are 2.3 and 2.3 respectively. The\nCurrent Ratio and Quick Ratio of its competitor TG Therapeutics Inc. are 1.7\nand 1.7 respectively. Myovant Sciences Ltd. therefore has a better chance of\npaying off short and long-term obligations compared to TG Therapeutics Inc.<\/p>\n\n\n\n
Analyst Recommendations<\/h2>\n\n\n\n
The\nfollowing table given below contains the ratings and recommendations for\nMyovant Sciences Ltd. and TG Therapeutics Inc.<\/p>\n\n\n\n
<\/td>
Sell Ratings <\/td>
Hold Ratings <\/td>
Buy Ratings <\/td>
Rating Score <\/td><\/tr>
Myovant Sciences Ltd<\/td>
\n 0\n <\/td>
\n 0\n <\/td>
\n 2\n <\/td>
\n 3.00\n <\/td><\/tr>
TG Therapeutics Inc.<\/td>
\n 0\n <\/td>
\n 0\n <\/td>
\n 2\n <\/td>
\n 3.00\n <\/td><\/tr><\/tbody><\/table>\n\n\n\n
The\naverage target price of Myovant Sciences Ltd. is $25.5, with potential upside\nof 213.27%. Competitively the average target price of TG Therapeutics Inc. is\n$17.5, which is potential 159.26% upside. The data from earlier shows that\nanalysts opinion suggest that Myovant Sciences Ltd. seems more appealing than\nTG Therapeutics Inc.<\/p>\n\n\n\n
Insider and Institutional Ownership<\/h2>\n\n\n\n
The\nshares of both Myovant Sciences Ltd. and TG Therapeutics Inc. are owned by\ninstitutional investors at 33.4% and 59% respectively. 56.5% are Myovant\nSciences Ltd.\u2019s share held by insiders. On the other hand, insiders held about\n0.4% of TG Therapeutics Inc.\u2019s shares.<\/p>\n\n\n\n
Performance<\/h2>\n\n\n\n
In\nthis table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and\nYTD Performance of both pretenders.<\/p>\n\n\n\n
<\/td>
Performance (W) <\/td>
Performance (M) <\/td>
Performance (Q) <\/td>
Performance (HY) <\/td>
Performance (Y) <\/td>
Performance (YTD) <\/td><\/tr>
Myovant SciencesLtd <\/td>
-9.21% <\/td>
-18.18% <\/td>
-59.09% <\/td>
-61.14% <\/td>
-63.47% <\/td>
-56.12% <\/td><\/tr>
TG Therapeutics Inc <\/td>
\n -2.09%\n <\/td>
-16.13% <\/td>
-3.85% <\/td>
72.98% <\/td>
-31.28% <\/td>
82.68% <\/td><\/tr><\/tbody><\/table>\n\n\n\n
For\nthe past year Myovant Sciences Ltd. has -56.12% weaker performance while TG\nTherapeutics Inc. has 82.68% stronger performance.<\/p>\n\n\n\n
About\nthe companies<\/h2>\n\n\n\n
Myovant\nSciences Ltd focuses on women\u2019s health and endocrine disorders. Their leading\nproduct is known as ead product is relugolix,\nan oral, once-daily, small molecule that acts as a gonadotropin-releasing\nhormone receptor antagonist. This is commonly used to treat heavy menstrual\nbleeding. is also developing MVT-602, an oligopeptide kisspeptin agonist,\nfor the treatment of female infertility as part of the hormonal preparation\nused in assisted reproduction.<\/p>\n\n\n\n
<\/figure><\/div>\n\n\n\n
TG Therapeutics Inc on the\nother hand focusses on B-cell malignancies and autoimmune diseases, primarily\nwithin the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered\nmonoclonal antibody that targets an epitope on the CD20 antigen found on the\nsurface of B-lymphocytes developed to aid in the depletion of circulating\nB-cells; and TG-1101 in combination with TGR-1202 for relapsed\/refractory\nnon-Hodgkin\u00c2\u2019s lymphoma and chronic lymphocytic leukemia. The company has\nlicense agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB\/GTC\nLLC, and Ildong Pharmaceutical Co. Ltd. for the development and\ncommercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the\ndevelopment and commercialization of TGR-1202; Ligand Pharmaceuticals\nIncorporated for the development and commercialization of IRAK4 inhibitor\ntechnology; Checkpoint Therapeutics, Inc. for the development and\ncommercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys, a\ncontract research organization<\/a>, for the development and commercialization of BET inhibitor\nprogram. TG Therapeutics, Inc. is headquartered in New York, New York.<\/p>\n","protected":false},"excerpt":{"rendered":"
![\"TG](\"https:\/\/www.futuresandoptions.gr\/en\/wp-content\/uploads\/2019\/08\/TG-Therapeutics.png\")
<\/figure><\/div>\n\n\n\n